🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 49 of 116

  1. GSK4418959

    IDEAYA Biosciences

    Neoplasms, Colorectal

    phase 2 small molecule active

    1 trial

  2. GT719 Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hematological Malignancy (Leukemia- Lymphoma)

    phase 2 mab active

    1 trial

  3. GTAEXS617

    RECURSION PHARMACEUTICALS, INC.

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  4. GTI-2040

    Aptose Biosciences

    Carcinoma, Renal Cell

    phase 2 small molecule completed

    1 trial

  5. GTI-2040

    Aptose Biosciences

    Acute Myeloid Leukemia

    phase 2 mab completed

    1 trial

  6. GVA + HDAC Consolidation & Gilteritinib Maintenance

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  7. GVM±R regimen

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Peripheral T Cell Lymphoma

    phase 2 small molecule active

    1 trial

  8. Gallium Ga 68 Gozetotide

    United Therapeutics Europe Ltd

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  9. Gamma-retroviral vector MP71 MC2 TCR16-3D9

    Disc Medicine

    advanced melanoma or HNSCC

    phase 2 small molecule active

    1 trial

  10. Ganoderma lucidum spore

    The First People's Hospital of Lianyungang

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  11. Gefitinib

    AstraZeneca

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  12. Gemcitabine

    ACTUATE THERAPEUTICS, INC.

    Soft Tissue Sarcoma

    phase 2 small molecule terminated

    1 trial

  13. Gemcitabine

    Compass Therapeutics

    Metastatic Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  14. Gemcitabine

    ACTUATE THERAPEUTICS, INC.

    Sarcoma

    phase 2 small molecule terminated

    1 trial

  15. Gemcitabine

    Chongqing Precision Biotech Co., Ltd

    Pancreatic Cancer, Adult

    phase 2 small molecule terminated

    1 trial

  16. Gemcitabine

    LEXICON PHARMACEUTICALS, INC.

    Locally Advanced Unresectable Pancreatic Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  17. Gemcitabine

    Regeneron UK Limited

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  18. Gemcitabine

    Acrivon Therapeutics

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  19. Gemcitabine

    Arcus Biosciences

    Biliary Tract Carcinoma

    phase 2 small molecule active

    1 trial

  20. Gemcitabine

    HALOZYME THERAPEUTICS, INC.

    Stage IV Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  21. Gemcitabine , Docetaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Sarcoma

    phase 2 small molecule completed

    1 trial

  22. Gemcitabine 100 mg/ml Concentrate for Solution for Infusion, 9-ING-41, Abraxane 5 mg/ml powder for dispersion for infusion.

    ACTUATE THERAPEUTICS, INC.

    Refractory Hematologic Malignancies or Solid Tumors

    phase 2 small molecule active

    1 trial

  23. Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, JNJ-42756493, Gemcitabine 2 g Powder for Solution for Infusion, JNJ-42756493, JNJ-42756493, Mitomycin medac 1 mg/ml Pulver zur Herstellung einer Injektions- bzw. Infusionslösung oder einer Lösung zur intravesikalen Anwendung

    Janssen-Cilag International N.V.

    Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions

    phase 2 small molecule active

    1 trial

  24. Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Padcev 30 mg powder for concentrate for solution for infusion, Zimberelimab, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, DOMVANALIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Bavencio 20 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Locally Advanced/Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  25. Gemcitabine Oxaliplatin 5FU and Leucovorin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  26. Gemcitabine plus Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  27. Gemcitabine+simvastatin

    Samsung Bioepis NL B.V.

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  28. Gemcitabine/Cisplatin

    BRIGHT MINDS BIOSCIENCES INC.

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  29. Genomically Directed Monotherapy

    Vera Therapeutics

    Malignant Neoplasm of Breast

    phase 2 small molecule completed

    1 trial

  30. Gentuximab

    The First People's Hospital of Lianyungang

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial

  31. Gentuximab

    Changchun GeneScience Pharmaceutical Co.,

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial

  32. Giapreza 2.5 mg/ml concentrate for solution for infusion

    Disc Medicine

    Liver cancer (primary or secondary)

    phase 2 small molecule active

    1 trial

  33. Gilteritinib

    Astellas Pharma Inc

    Non-Small-Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  34. Gimistotug

    BEONE MEDICINES AUS PTY LTD

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  35. Giredestrant

    Hoffmann-La Roche

    Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  36. Giredestrant

    Hoffmann-La Roche

    Early Breast Cancer

    phase 2 small molecule completed

    1 trial

  37. Givinostat 75 mg capsules, Givinostat 100 mg capsules, Givinostat 50 mg capsules

    Italfarmaco S.p.A.

    Chronic myeloproliferative neoplasm

    phase 2 small molecule active

    1 trial

  38. Glasdegib

    Jazz Pharmaceuticals Ireland Limited

    Acute Myelogenous Leukemia (AML) Due to Therapy

    phase 2 small molecule active

    1 trial

  39. Gliolan 30 mg/ml powder for oral solution.

    Photonamic GmbH & Co. KG

    Colorectal Carcinoma

    phase 2 small molecule active

    1 trial

  40. Glofitamab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed or Refractory Aggressive B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  41. Glofitamab, Gazyvaro 1,000 mg concentrate for solution for infusion., MabThera 500 mg concentrate for solution for infusion, Polivy 140 mg powder for concentrate for solution for infusion.

    The George Institute

    previously untreated aggressive B-cell lymphoma

    phase 2 small molecule active

    1 trial

  42. GnP in combination with Ivonescimab and SBRT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 other active

    1 trial

  43. Green tea

    United Therapeutics Europe Ltd

    Lung Cancer Prevention

    phase 2 other completed

    1 trial

  44. Group A (FIT): Avapritinib + IA regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia With T(8;21)(Q22;Q22)

    phase 2 small molecule active

    1 trial

  45. Group A：Patients with PR or ctDNA positivity after salvage treatment

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma(DLBCL)

    phase 2 small molecule active

    1 trial

  46. HAIC + Tislelizumab +lenvatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma (HCC)

    phase 2 other active

    1 trial

  47. HCD122

    Novartis Pharmaceuticals

    Non-Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  48. HEC169096

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.